Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5678596 | Contemporary Clinical Trials | 2017 | 7 Pages |
Abstract
One of the most important problems in transplantation medicine is the ischemia/reperfusion injury of the organs to be transplanted. The aim of the present study was to assess the effect of tumor necrosis factor-alpha (TNF-alpha) inhibitor etanercept on the machine perfusion hypothermia of renal allograft kidney function and organ perfusion. No statistically significant differences were found in the impact of the applied intervention on kidney machine perfusion during which the average flow and vascular resistance were evaluated. There were no statistically significant differences in the occurrence of delayed graft function (DGF). Fewer events in patients who received a kidney from the etanercept treated Group A compared to the patients who received a kidney from the control Group B were observed when comparing the functional DGF and occurrence of acute rejection episodes, however, there was no statistically significant difference. In summary, no effect of treatment with etanercept an inhibitor of TNF-alpha in a hypothermic machine perfusion on renal allograft renal survival and its perfusion were detected in this study. However, treatment of the isolated organ may be important for the future of transplantation medicine.
Keywords
HMPPRADGFPRUCITECDSCDTNFTITRheumatoid arthritisIschemia-reperfusion injuryPanel reactive antibodyexpanded criteria donorsdelayed graft functionUniversity of WisconsinTreatmentPeritoneal dialysisCold storageAcute rejectioncold ischemia timeprimary non-functionconfidence intervaltumor necrosis factorBrain deathhazard ratioHemodialysisPNFHypothermic machine perfusionRegenerative medicineKidney transplantation
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Piotr Diuwe, Piotr Domagala, Magdalena Durlik, Janusz Trzebicki, Andrzej Chmura, Artur Kwiatkowski,